# An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

> **NCT01753193** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 218 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **BIOLOGICAL:** Anifrolumab

## Key facts

- **NCT ID:** NCT01753193
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-28
- **Primary completion:** 2018-07-18
- **Final completion:** 2018-07-18
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01753193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01753193, "An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01753193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*